Cantor Fitzgerald Brokers Raise Earnings Estimates for LLY

Eli Lilly and Company (NYSE:LLY) – Equities researchers at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Eli Lilly and Company in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now forecasts that the company will post earnings per share of $23.25 for the year, up from their prior estimate of $21.76. Cantor Fitzgerald currently has a “Overweight” rating and a $825.00 price objective on the stock. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $23.48 per share. Cantor Fitzgerald also issued estimates for Eli Lilly and Company’s FY2026 earnings at $33.00 EPS.

LLY has been the topic of several other reports. Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Finally, Guggenheim cut their target price on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $964.88.

Eli Lilly and Company Trading Up 2.5%

NYSE LLY opened at $701.51 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $972.53. The company has a market cap of $663.95 billion, a price-to-earnings ratio of 45.85, a price-to-earnings-growth ratio of 0.98 and a beta of 0.44. The business’s fifty day moving average is $764.55 and its 200 day moving average is $794.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. Eli Lilly and Company’s dividend payout ratio is 39.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the company. WestEnd Advisors LLC lifted its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $27,000. Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $31,000. Finally, Bare Financial Services Inc lifted its position in shares of Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.